New Horizon Health Limited 

$0
0
+$0+0% Monday 00:00

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

財務

-10.52%利潤率
未盈利
2018
2019
2020
2021
2022
111.88M營收
-11.77M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 NHZHY 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Show more...
執行長
Mr. Yeqing Zhu
員工
1041
國家
DE
ISIN
US64551U1025

上市

0 Comments

分享你的想法

FAQ

New Horizon Health Limited 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,New Horizon Health Limited 的股票以代號 NHZHY 進行交易。
New Horizon Health Limited 去年的營收是多少?
New Horizon Health Limited 去年的營收為 111.88MUSD。
New Horizon Health Limited 去年的淨利是多少?
NHZHY 去年的淨收益為 -11.77MUSD。
New Horizon Health Limited 有多少名員工?
截至 April 07, 2026,公司共有 1,041 名員工。
New Horizon Health Limited 何時完成拆股?
New Horizon Health Limited 最近沒有進行任何拆股。
New Horizon Health Limited 的總部在哪裡?
New Horizon Health Limited 的總部位於 DE 的 Hangzhou。